ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $191,280.00 in Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Sophia Randolph sold 12,000 shares of the company's stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the sale, the insider now directly owns 330,349 shares in the company, valued at approximately $5,265,763.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

ALX Oncology Stock Down 1.0 %

ALXO stock traded down $0.15 during midday trading on Wednesday, reaching $15.02. 321,855 shares of the company's stock traded hands, compared to its average volume of 455,336. The company has a quick ratio of 5.21, a current ratio of 5.21 and a debt-to-equity ratio of 0.06. The firm's fifty day moving average price is $13.83 and its 200-day moving average price is $13.04. ALX Oncology Holdings Inc. has a 52 week low of $3.94 and a 52 week high of $17.83. The company has a market cap of $782.54 million, a price-to-earnings ratio of -4.16 and a beta of 1.30.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last announced its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.09). As a group, sell-side analysts forecast that ALX Oncology Holdings Inc. will post -3.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ALXO. Cantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research report on Friday, April 12th. Stifel Nicolaus reaffirmed a "hold" rating and set a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of ALX Oncology in a research note on Wednesday, April 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $18.83.

Institutional Investors Weigh In On ALX Oncology

A number of hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of ALX Oncology during the 3rd quarter valued at $48,000. Barclays PLC increased its stake in shares of ALX Oncology by 57.1% in the third quarter. Barclays PLC now owns 26,964 shares of the company's stock worth $129,000 after purchasing an additional 9,796 shares in the last quarter. Forefront Analytics LLC bought a new stake in shares of ALX Oncology in the third quarter valued at approximately $66,000. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of ALX Oncology in the third quarter valued at approximately $96,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of ALX Oncology during the 3rd quarter valued at approximately $168,000. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.